Grace Therapeutics, Inc. (GRCE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Grace Therapeutics, Inc. (formerly Acasti Pharma Inc.) on October 24, 2024. The report details a corporate name change and the associated amendment to the Company's Certificate of Incorporation and Bylaws. The name change became effective on October 28, 2024.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event filing regarding corporate governance and does not contain financial performance data.
Material Changes
- Corporate Name: Changed from "Acasti Pharma Inc." to "Grace Therapeutics, Inc."
- Trading Symbol: The common stock ticker symbol changed from "ACST" to "GRCE" on the Nasdaq Stock Market, effective October 28, 2024.
- Governance Documents: The Certificate of Incorporation and Bylaws were amended solely to reflect the new name.
Outlook, Risks, and Commentary
Management stated that the name change does not affect the rights of the Company's security holders. The CUSIP number for the common stock remains 00439U104. No guidance, risks, contingencies, or unusual items were disclosed in this specific filing.
Key Facts for Investor Verification
- Verify the new ticker symbol "GRCE" on trading platforms effective October 28, 2024.
- Confirm that the CUSIP number 00439U104 remains unchanged for existing holdings.
- Review the attached Certificate of Amendment (Exhibit 3.1) and Bylaws (Exhibit 3.2) for the official legal documentation of the name change.